Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis

Podobne zapisy

• Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
  od: Uchino, Junji, i wsp.
  Wydane: (2018)
• Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
  od: Takayuki, Nakano, i wsp.
  Wydane: (2018)
• Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)
  od: Chihara, Yusuke, i wsp.
  Wydane: (2019)
• Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
  od: Katayama, Yuki, i wsp.
  Wydane: (2019)
• Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
  od: Yamada, Tadaaki, i wsp.
  Wydane: (2020)